Fig. 3From: Efficacy and safety analysis of TACE + sunitinib vs. sunitinib in the treatment of unresectable advanced renal cell carcinoma: a retrospective studyOverall survival of patients in two groupsmOS: TACE + Sunitinib group, 35.0 months (95% CI 32.7–37.4 months); Sunitinib group, 25.7 months (95% CI 23.6–27.8 months).Back to article page